Vanda Pharmaceuticals
VNDA
117 hedge funds and large institutions have $396M invested in Vanda Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 36 reducing their positions, and 25 closing their positions.
87% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $2.26M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 36
4% less funds holding
Funds holding: 122 → 117 (-5)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
18% less capital invested
Capital invested by funds: $481M → $396M (-$85.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$12.1M |
| 2 |
AC
Armistice Capital
New York
|
+$8.68M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$4.2M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.84M |
| 5 |
Renaissance Technologies
New York
|
+$3.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$11.3M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$10.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$8.62M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.46M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.98M |
VNDA Hedge Fund Activity: Q4 2015 in Review
117 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2015, worth a combined $396M — down 18% from $481M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of VNDA and 21 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 33 added.
The largest buyer was Deerfield Management, adding an estimated $12.1M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $11.3M sold.
- 117 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2015, down from 122 in Q3 2015.
- Funds reported $396M of Vanda Pharmaceuticals stock for Q4 2015, down 18% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q4 2015 and 25 closed out, a net change of -4 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2015 was Deerfield Management, an estimated $12.1M added.
- The largest Vanda Pharmaceuticals seller in Q4 2015 was EverPoint Asset Management, an estimated $11.3M sold.
Based on aggregated 13F filings for Q4 2015.